Abogen Biosciences
Comment: Not all statements in the draft have citations when they should. For example, the first paragraph in the History section lacks citations. Also, please be mindful of using the term "novel", as that can come across as not neutral. Z. Patterson (talk) 00:43, 19 August 2026 (UTC)
- Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. Jaimebai (talk) 05:59, 4 June 2026 (UTC)
Abogen is a clinical-stage biotechnology company dedicated to the development of novel medicines through RNA-based technology innovations.
History
Established in 2019, the company has built in-house capabilities to support the entire mRNA drug development cycle — from protein engineering, mRNA sequence design and synthesis, lipid nanoparticle (LNP) delivery, formulation, all the way to commercial-scale manufacturing.
In 2020, Abogen partnered with Walvax Biotechnology to develop ARCoV, an mRNA COVID-19 vaccine candidate. In June the same year, the COVID-19 vaccine candidate became the first mRNA vaccine approved for clinical trials by China's National Medical Products Administration (NMPA).[1]
In 2021, Abogen secured $1 billion across two funding rounds, which accounted for approximately 3.5% of the total private biotech funding raised worldwide, and topped the global ranking in Evaluate Vintage's year-end report.[2]
In 2022, Abogen received Emergency Use Authorization (EUA) from Indonesia's Food and Drug Supervisory Agency (BPOM) for ARCoV.[3]
In 2024, Abogen announced the publication of "Efficient circularization of protein-encoding RNAs via a novel cis-splicing system" in Nucleic Acids Research, describing a cis-splicing system for circular RNA (circRNA) production designed to extend protein expression and reduce innate immune activation.[4] Later that year, Abogen and Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, co-founded the Nucleic Acid Drug Research Institute. [5] Abogen's intellectual property portfolio related to mRNA technology and products ranked fourth globally in terms of patent filing activities in 2024, alongside BioNTech, Moderna, Sanofi and Pfizer. [6]
In 2025, Abogen announced that ABO2102, an mRNA cancer vaccine targeting KRAS-mutant solid tumors, obtained IND approvals from both China's NMPA and the US FDA.[7][8] At the 2025 AACR Annual Meeting, Abogen presented data on ABO2013, an EGFR neoantigen-specific mRNA vaccine candidate for non-small cell lung cancer (NSCLC), reporting immunogenicity in human immune cell studies and anti-tumor activity in mouse models. [9] Abogen's RSV and VZV mRNA vaccine candidates entered Phase II clinical trials in September and November 2025, respectively. [10][11]
In April 2026, Abogen presented preliminary data at the AACR Annual Meeting from a first-in-human (FIH) study of ABO2203, an mRNA-encoded CD3×CD19 bispecific T-cell engager (TCE), in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Among the nine patients treated at doses up to 1,920 μg, no dose-limiting toxicities, cytokine release syndrome, or ICANS were observed, and maximum tolerated dose was not reached.[12] In May 2026, Abogen announced that research on ABO2203 for refractory autoimmune diseases had been selected for a Poster Tour Presentation at the EULAR 2026 Congress. The candidate demonstrated gradual in vivo expression and rapid B-cell depletion without steroid premedication, supporting potential outpatient subcutaneous administration. [13]
References
- ↑ "China's first COVID-19 mRNA vaccine approved for clinical trials". english.nmpa.gov.cn. Retrieved 2026-05-27.
- ↑ Bayer, Max (2022-04-18). "Biotech venture capital: Top 10 money-raisers of 2021". www.fiercebiotech.com. Retrieved 2026-05-27.
- ↑ antaranews.com (2022-09-30). "AWcorna becomes first domestically produced mRNA COVID-19 vaccine". Antara News. Retrieved 2026-05-27.
- ↑ Qi, Shaojun; Wang, Huiming; Liu, Guopeng; Qin, Qianshan; Gao, Peng; Ying, Bo (2024-09-23). "Efficient circularization of protein-encoding RNAs via a novel cis -splicing system". Nucleic Acids Research. 52 (17): 10400–10415. doi:10.1093/nar/gkae711. ISSN 0305-1048. PMC 11417360 Check
|pmc=value (help). PMID 39162233 Check|pmid=value (help). - ↑ "Hospital and company jointly inaugurate a research institute in SIP_Industries & Enterprises". www.sipac.gov.cn. Retrieved 2026-05-27.
- ↑ knowmade (2025-01-30). "2024 mRNA Patent Trends: Key Insights & Industry Leaders". KnowMade. Retrieved 2026-05-27.
- ↑ "Clinical Trial Registration Information for CTR20255113". www.chinadrugtrials.org.cn. Retrieved 2026-05-27.
- ↑ Suzhou Abogen Biosciences Co., Ltd. (2026-04-03). A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of ABO2102 in Participants With KRAS Mutant Solid Tumors (Report). clinicaltrials.gov.
- ↑ Wenhua Liang; Bo Cheng; Jingshu Ma; Yan Wu; Liang Du; Peng Gao; Zhenxing Yang; Wenjie Song; Bo Ying; Jianxing He (15 April 2025). "Abstract 852: A novel EGFR neoantigen-specific mRNA cancer vaccine demonstrates immunogenicity and anti-tumor efficacy in human". Cancer Research. 85 (8_Supplement_1): 852. doi:10.1158/1538-7445.AM2025-852 – via AACR Journals Online.CS1 maint: Multiple names: authors list (link)
- ↑ "Clinical Trial Registration Information for CTR20253567". www.chinadrugtrials.org.cn. Retrieved 2026-05-27.
- ↑ "Clinical Trial Registration Information for CTR20254264". www.chinadrugtrials.org.cn. Retrieved 2026-05-27.
- ↑ "AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL". AP News. 2026-04-20. Retrieved 2026-05-27.
- ↑ "Programme at a glance". pag.virtual-meeting.org. Retrieved 2026-05-27.
This article "Abogen Biosciences" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Abogen Biosciences. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
